Vaxart(VXRT) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - Revenue for the full year 2025 was $237.3 million, a significant increase from $28.7 million in 2024, primarily driven by government contracts and the Dynavax collaboration [20] - Cash equivalents and investments at the end of the fourth quarter were $63.8 million, with an expected cash runway into the second quarter of 2027 [20][21] Business Line Data and Key Metrics Changes - The partnership with Dynavax for the oral COVID-19 vaccine candidate included a $25 million upfront payment and a $5 million equity investment, validating the oral vaccine platform [5][6] - The oral norovirus vaccine candidate showed promising results in a clinical study, with significant increases in IgA levels in both serum and breast milk [14][15][17] Market Data and Key Metrics Changes - The COVID-19 vaccine trial is currently in phase 2B, with a focus on comparing the oral vaccine's efficacy against an mRNA vaccine [9][10] - The need for next-generation solutions in COVID-19 vaccination remains critical as the pandemic continues to impact global health [11] Company Strategy and Development Direction - The company aims to manage financial resources effectively, pursuing strategic partnerships and reducing operating costs to focus on advancing lead programs [7][21] - The oral pill vaccine platform is viewed as a disruptive technology that could address public health challenges and changing vaccination preferences [24] Management's Comments on Operating Environment and Future Outlook - Management remains optimistic about the potential of the COVID-19 and norovirus oral vaccine programs to provide public health benefits and create shareholder value [22] - The company plans to report top-line results from the COVID-19 trial's sentinel cohort in early Q2 2026 and from the KP2 cohort in Q4 2026 [23] Other Important Information - A lease termination agreement was entered into to reduce operating expenses, allowing for a more focused allocation of financial resources [5][8] - The company is exploring licensing or partnership opportunities for earlier-stage assets, including seasonal and pandemic flu candidates and the HPV program [24] Q&A Session Summary Question: Delay in 400-person sentinel cohort data - Management acknowledged a slight delay in reporting the 400-person sentinel cohort data, now expected in early Q2 instead of late Q1, due to interactions with BARDA [27][28] Question: Next steps after sentinel data - The decision points for next steps will involve both BARDA and Dynavax, with Vaxart overseeing the Phase 2B trial [36][37] Question: Immunogenicity data availability - Immunogenicity data will not be included in the Q2 update but will follow after the initial safety data [36][39] Question: Regulatory input on norovirus candidate - Discussions with the FDA have occurred regarding the primary endpoint of safety for the next phase 2 study of the norovirus candidate [42][43]